Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Drug Resistance in Pneumonia (DRIP) Score

    Predicts risk for community-acquired pneumonia due to drug-resistant pathogens.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with community acquired pneumonia.

    • Should be utilized only for bacterial causes of pneumonia.
    • False negatives can be seen in the following situations: MRSA or P. aeruginosa infection, severe COPD (requiring O₂ and steroids), IV drug use, psychiatric conditions, and homelessness.
    • False positives can be seen with S. pneumoniae and MSSA.
    • The DRIP validation study evaluated a broader set of risk factors than the HCAP definition.
    • The DRIP study reaffirmed that antibiotic use and hospitalization 60 days prior are major contributors to drug resistance, but did not find a strong association between severity of illness and drug resistance.
    • More predictive of drug resistant pathogens compared to HCAP and may have the potential to decrease antibiotic over-utilization in pneumonia.
    • Decreases use of unnecessary extended-spectrum antibiotics by 46% as compared with the HCAP definition.
    • At a cut-off of ≥4 points, DRIP optimally differentiates high and low risk (PPV of 73.0, NPV 92.0, AUROC 0.88, accuracy of 87%), supporting its utility as a clinical decision tool to guide empiric antibiotic selection. Accuracy was defined as “percent of cases in which antibiotic spectrum (that would have been recommended based on DRIP classification) would have been appropriate for the recovered organism.”
    Major Risk Factors
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    Minor Risk Factors
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    The goal of the DRIP Score is to determine when broad spectrum antibiotics should be used, both to be effective with treatment and to avoid increasing antibiotic resistance.

    Management

    • A patient with a DRIP Score <4 can effectively be treated without broad-spectrum antibiotic coverage.
    • A patient with a DRIP Score of ≥4 is more likely to require broad-spectrum antibiotic coverage.

    Formula

    Addition of the selected points:

    Risk Factor

    Points

    Major

    Antibiotic use within 60 days

    2

    Long term care resident*

    2

    Tube feeding**

    2

    Prior drug-resistant pneumonia within 1 year

    2

    Minor

    Prior hospitalization  within 60 days

    1

    Chronic pulmonary disease

    1

    Poor functional status***

    1

    H2 blocker or PPI within 14 days

    1

    Active wound care at time of admission

    1

    MRSA colonization within 1 year

    1

    *Including long term acute care, skilled nursing, and inpatient rehabilitation but not assisted living or group home facilities.

    **Nasogastric, nasojejunal, or percutaneous gastrostomy.

    ***Karnofsky Performance Status <70 or non-ambulatory status.

    Facts & Figures

    Interpretation:

    DRIP Score

    Interpretation

    <4

    Low risk of drug-resistant pneumonia. Consider treating without extended-spectrum antibiotics.

    ≥4

    High risk of drug-resistant pneumonia. Extended-spectrum antibiotics likely necessary.

    Evidence Appraisal

    • Webb et al created the DRIP Score with their study that both derived and validated a clinical prediction tool to help predict which cases of bacterial pneumonia may be antibiotic resistant. Their research goal was to create a predictive score more accurate than HCAP.   
    • During the derivation portion of the study, multiple risk factors for drug resistant pathogens were evaluated using logistic regression for a cohort of 200 cases of confirmed bacterial pneumonia.
    • Compared to HCAP, the DRIP Score is more sensitive (82% vs 79%), more specific (81% vs 65%), and decreases use of unnecessary extended-spectrum antibiotics by 46%.
    • The DRIP Score was also more specific and more accurate than eight other predictive models, including the Shorr Score.
    Dr. Brandon Webb

    From the Creator

    Why did you develop the DRIP Score? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?

    I developed the idea for the DRIP Score while working as a hospitalist before my infectious disease fellowship. I frequently admitted patients with pneumonia who met HCAP criteria, and yet few of them ended up requiring the vancomycin and broad-spectrum gram negative antibiotics we were giving.  

    When I started digging into the literature, I was surprised to find that use of these antibiotics had doubled in the last 10 years without an increase in rates of antibiotic-resistant bacteria! This led to the development of a score that would help clinicians more accurately decide which patients can safely be treated for community-acquired pneumonia.

    What pearls, pitfalls and/or tips do you have for users of the DRIP Score? Do you know of cases when it has been applied, interpreted, or used inappropriately?

    The DRIP Score was designed to improve specificity (less false positive identification of patients who don't have antibiotic resistant bugs), without sacrificing sensitivity (false negatives lead to inadequate antibiotic spectrum). No score is perfect, and DRIP is no exception. We are getting ready to report results of implementation of DRIP in nearly 2,000 patients and one thing we observed is that there are some patients, particularly with chronic pulmonary diseases, who have scores <4 but are colonized with MRSA or Pseudomonas. It is sometimes difficult to determine which of these patients truly have a true lower tract infection due these drug-resistant organisms from a sputum culture alone, however. Some clinicians at our institution are using a "clinical margin for error" approach - in critically-ill patients on vasopressors or mechanical ventilation, they consider using a threshold of 3 points or higher to initiate broad spectrum antibiotics.

    What recommendations do you have for doctors once they have applied the DRIP Score? Are there any adjustments or updates you would make to the score based on new data or practice changes?

    I have two recommendations for clinicians using DRIP: first, it is important to know what your local microbiology rates are. While many hospitals have low rates of MRSA and Pseudomonas as causes of community-onset pneumonia, DRIP may not work as well in some institutions and in some distinct patient populations such as transplant recipients with high multidrug-resistant organism (MDRO) prevalence.  

    My second recommendation is to consider deescalating antibiotics in patients with DRIP >4 who are started on broad spectrum regimens if no resistant organism is identified and the patient has achieved clinical stability. In our hospitals, we couple the DRIP score with the MRSA nasal PCR, which has a very strong NPV and allows clinicians to deescalate vancomycin earlier if negative. The PPV is not stellar, so even if it is positive but no MRSA is found in the blood or respiratory sample, vancomycin can often still be stopped.

    How do you use the DRIP Score in your own clinical practice? Can you give an example of a scenario in which you use it?

    At the 21 Intermountain healthcare hospitals, calculating DRIP is part of the order sets in our ED and hospitalist/intensivist bundles.

    Any other research in the pipeline that you’re particularly excited about?

    DRIP has now been implemented in several places around the country and we are looking forward to publication of several centers' experience using it, including our own.

    About the Creator

    Brandon Webb, MD, is a practicing infectious disease physician in the division of epidemiology and infectious diseases at Intermountain Healthcare in Utah. He has also served as an adjunct assistant professor at the University of Utah School of Medicine. Dr. Webb's research interests include bacterial pneumonia, antimicrobial stewardship, and transplant infectious diseases.

    To view Dr. Brandon Webb's publications, visit PubMed

    Content Contributors
    • John Dayton, MD
    About the Creator
    Dr. Brandon Webb
    Content Contributors
    • John Dayton, MD